References
- Bensmail D, Vermersch P. Epidemiology and clinical assessment of spasticity in multiple sclerosis. Rev Neurol (Paris) 2012;168(Suppl 3):S45–S50.
- Kister I, Bacon TE, Chamot E, et al. Natural history of multiple sclerosis symptoms. Int J MS Care 2013;15(3):146–158.
- Bethoux F, Marrie RA. A cross-sectional study of the impact of spasticity on daily activities in multiple sclerosis. Patient 2016;9(6):537–546.
- Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis - Clinical characteristics, treatment and quality of life. Acta Neurol Scand. 2014;129(3):154–162.
- Arroyo R, Massana M, Vila C. Correlation between spasticity and quality of life in patients with multiple sclerosis: The CANDLE study. Int J Neurosci. 2013;123(12):850–858.
- Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler. 2016;22(11):1386–1396.
- Henze T, Feneberg W, Flachenecker P, et al. What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity. Nervenarzt 2017;88(12):1428–1434.
- eMC Sativex Oromucosal Spray SPC. 2018. [cited 2019 September 5]. Available from: https://www.medicines.org.uk/emc/history/23262.
- Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo- controlled study on 160 patients. Mult Scler. 2004;10(4):434–441.
- Collin C, Davies P, Mutiboko IK, et al.; for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290–296.
- Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451–459.
- Novotna A, Mares J, Ratcliffe S, et al.; The Sativex Spasticity Study Group. A randomized, double-blind, placebo-controlled, parallel- group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–1131.
- Markovà J, Essner U, Akmaz B, et al. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int J Neurosci. 2019;129(2):119–128.
- Lucchinetti C, Brack W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707–717.